These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

271 related items for PubMed ID: 15322960

  • 21.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 22.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 23.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 24.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 25. Dexmethylphenidate extended-release capsules in children with attention-deficit/hyperactivity disorder.
    Silva RR, Muniz R, Pestreich L, Brams M, Mao AR, Childress A, Wang J.
    J Am Acad Child Adolesc Psychiatry; 2008 Feb; 47(2):199-208. PubMed ID: 18176337
    [Abstract] [Full Text] [Related]

  • 26.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 27. What can actigraphy add to the concept of labschool design in clinical trials?
    Uebel H, Albrecht B, Kirov R, Heise A, Döpfner M, Freisleder FJ, Gerber WD, Günter M, Hässler F, Ose C, Poustka F, Fischer R, Banaschewski T, Rothenberger A.
    Curr Pharm Des; 2010 Feb; 16(22):2434-42. PubMed ID: 20513227
    [Abstract] [Full Text] [Related]

  • 28. A randomized, double-blind, placebo-controlled, parallel-group study of methylphenidate transdermal system in pediatric patients with attention-deficit/hyperactivity disorder.
    Findling RL, Bukstein OG, Melmed RD, López FA, Sallee FR, Arnold LE, Pratt RD.
    J Clin Psychiatry; 2008 Jan; 69(1):149-59. PubMed ID: 18312050
    [Abstract] [Full Text] [Related]

  • 29.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 30.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 31. Long-acting methylphenidate formulations in the treatment of attention-deficit/hyperactivity disorder: a systematic review of head-to-head studies.
    Coghill D, Banaschewski T, Zuddas A, Pelaz A, Gagliano A, Doepfner M.
    BMC Psychiatry; 2013 Sep 27; 13():237. PubMed ID: 24074240
    [Abstract] [Full Text] [Related]

  • 32.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 33.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 34. OROS-methylphenidate efficacy on specific executive functioning deficits in adults with ADHD: a randomized, placebo-controlled cross-over study.
    Bron TI, Bijlenga D, Boonstra AM, Breuk M, Pardoen WF, Beekman AT, Kooij JJ.
    Eur Neuropsychopharmacol; 2014 Apr 27; 24(4):519-28. PubMed ID: 24508533
    [Abstract] [Full Text] [Related]

  • 35. Efficacy and safety of extended-release dexmethylphenidate compared with d,l-methylphenidate and placebo in the treatment of children with attention-deficit/hyperactivity disorder: a 12-hour laboratory classroom study.
    Muniz R, Brams M, Mao A, McCague K, Pestreich L, Silva R.
    J Child Adolesc Psychopharmacol; 2008 Jun 27; 18(3):248-56. PubMed ID: 18582179
    [Abstract] [Full Text] [Related]

  • 36. A comparison of morning-only and morning/late afternoon Adderall to morning-only, twice-daily, and three times-daily methylphenidate in children with attention-deficit/hyperactivity disorder.
    Pelham WE, Gnagy EM, Chronis AM, Burrows-MacLean L, Fabiano GA, Onyango AN, Meichenbaum DL, Williams A, Aronoff HR, Steiner RL.
    Pediatrics; 1999 Dec 27; 104(6):1300-11. PubMed ID: 10585981
    [Abstract] [Full Text] [Related]

  • 37. A Randomized, Double-Blind, Placebo-Controlled Study of HLD200, a Delayed-Release and Extended-Release Methylphenidate, in Children with Attention-Deficit/Hyperactivity Disorder: An Evaluation of Safety and Efficacy Throughout the Day and Across Settings.
    Childress AC, Cutler AJ, Marraffino A, McDonnell MA, Turnbow JM, Brams M, DeSousa NJ, Incledon B, Sallee FR, Wigal SB.
    J Child Adolesc Psychopharmacol; 2020 Feb 27; 30(1):2-14. PubMed ID: 31464511
    [Abstract] [Full Text] [Related]

  • 38.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 39. Comparative pharmacodynamics and plasma concentrations of d-threo-methylphenidate hydrochloride after single doses of d-threo-methylphenidate hydrochloride and d,l-threo-methylphenidate hydrochloride in a double-blind, placebo-controlled, crossover laboratory school study in children with attention-deficit/hyperactivity disorder.
    Quinn D, Wigal S, Swanson J, Hirsch S, Ottolini Y, Dariani M, Roffman M, Zeldis J, Cooper T.
    J Am Acad Child Adolesc Psychiatry; 2004 Nov 27; 43(11):1422-9. PubMed ID: 15502602
    [Abstract] [Full Text] [Related]

  • 40. Acute tolerance to methylphenidate in the treatment of attention deficit hyperactivity disorder in children.
    Swanson J, Gupta S, Guinta D, Flynn D, Agler D, Lerner M, Williams L, Shoulson I, Wigal S.
    Clin Pharmacol Ther; 1999 Sep 27; 66(3):295-305. PubMed ID: 10511066
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 14.